Sunshine Heart Inc (NASDAQ:CHFS) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus target price of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 170 out of 265 based on the ratings given to its competitors.

Several analysts have issued reports on the stock. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 31st. Zacks Investment Research downgraded shares of Sunshine Heart from a “buy” rating to a “hold” rating in a report on Friday, January 5th.

Shares of Sunshine Heart (CHFS) traded down $0.23 during midday trading on Friday, hitting $3.03. 354,040 shares of the company’s stock traded hands, compared to its average volume of 652,289. Sunshine Heart has a 12 month low of $2.87 and a 12 month high of $111.40. The stock has a market capitalization of $6.04, a P/E ratio of -0.02 and a beta of 2.34.

TRADEMARK VIOLATION WARNING: “” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with's FREE daily email newsletter.